Malignant Ovarian Tumor Imaging
No Results
No Results
processing….
Ovarian cancer is a silent killer; however, improvements in identification of women at high risk for ovarian cancer, as well as improved imaging techniques, have increased the likelihood of early detection. [1, 2, 3] Primary ovarian, fallopian tube, and peritoneal high-grade serous ovarian cancer (HGSOC high-grade serous ovarian cancer) is the most prevalent and lethal histologic subtype of epithelial ovarian cancer, partly because it is frequently diagnosed at advanced stages. [4]
Pelvic ultrasonography is the examination of choice, followed by magnetic resonance imaging (MRI) and/or computed tomography (CT) scanning. [5, 6, 7] The ovary may be difficult to delineate in some women who are postmenopausal, because of its relatively small size (< 2 × 2 cm), its position deep within the pelvis, and the lack of identifiable contained structures, such as cysts. [8, 9, 10, 11] Relatively simple ultrasound-based rules can be used to diagnose ovarian malignancy, such as the International Ovarian Tumor Analysis (IOTA) rules. [2, 3] The American College of Radiology, U.S. Preventive Services Task Force, American College of Obstetricians and Gynecologists, Society of Gynecologic Oncologists, and National Comprehensive Cancer Network have published guidelines on imaging for ovarian cancer (see Guidelines, below).
(See the images and video below.)
American College of Radiology (ACR)
The ACR appropriateness criteria does not recommend that women at average risk for ovarian cancer receive screening imaging. Women at a high risk of ovarian cancer may benefit from screening. Pre- and postmenopausal women are considered to have a high risk of ovarian cancer if they have a personal or family history of ovarian cancer, have or are suspected to have BRCA1 or BRCA2 genetic mutations, or have an elevated CA-125 level (antigen 125—a protein elevated in cancer tumor cells) as measured by a blood test. The recommended imaging test to screen for ovarian cancer is ultrasound (US) to visualize the ovaries. These tests include transvaginal US (preferred), transabdominal US (in women who are not good candidates for transvaginal US), and US color Doppler (allows for visualization of blood flow). CT and MRI are usually not appropriate for screening women with either average or high risk of ovarian cancer. [12]
ACR appropriateness recommendations for evaluation of adnexal mass include the following [13] :
ACR appropriateness criteria for the initial staging of ovarian cancer recommends contrast-enhanced CT (with oral contrast) of the abdomen and pelvis as the imaging modality of choice, with inclusion of the chest where indicated. These examinations are complementary and should be performed together. Contrast-enhanced CT of the abdomen and pelvis (with oral contrast) or CT of the chest, abdomen, and pelvis are the modalities of choice for the extent of disease in suspected recurrence, and FDG-PET/CT is also usually appropriate, as it can provide management-changing information about unresectable sites of tumor or small lymph nodes. CT and FDG-PET/CT are considered equivalent alternatives. [14]
U.S. Preventive Services Task Force (USPSTF)
The U.S. Preventive Services Task Force (USPSTF) has concluded that annual screening of asymptomatic women with transvaginal ultrasonography and testing for a serum tumor marker, cancer antigen (CA)–125, does not reduce ovarian cancer deaths, but can lead to major surgical interventions in women who do not have cancer. With the harms of screening outweighing the benefits, USPSTF recommends against routine screening. [15]
The consensus among major medical organizations is in agreement with the USPSTF that screening for ovarian cancer in the general population is not recommended. However, the American College of Obstetricians and Gynecologists (ACOG) and the Society of Gynecologic Oncologists (SGO) recommend that women at high risk be offered an evaluation includes transvaginal ultrasonography, CA-125 testing, and a thorough pelvic examination. [16]
Society of Gynecologic Oncology and the American Society of Clinical Oncology
Guidelines from the Society of Gynecologic Oncology and the American Society of Clinical Oncology recommend that the primary clinical evaluation for ovarian cancer include a computed tomography (CT) scan of the abdomen and pelvis with oral and intravenous contrast, and chest imaging (CT preferred) to evaluate the extent of disease and the feasibility of surgical resection. [16]
National Comprehensive Cancer Network
National Comprehensive Cancer Network guidelines recommend chest x-ray or CT, as clinically indicated, and ultrasound and/or abdominal/pelvic CT or magnetic resonance imaging (MRI), as clinically indicated. Positron emission tomography (PET)/CT scan or MRI may be indicated for indeterminate lesions, if the results will alter management. [17]
MRI can increase the specificity of imaging evaluation in cases where the ultrasound appearance of the lesion is indeterminate. [ 8 ] MRI is not definitive, however. On MRI, endometriotic cysts with enhanced mural nodules are a hallmark of ovarian cancer, but they may also be a feature of benign neoplasms and even inflammatory diseases. Large contrast-enhanced nodules on large endometriotic cysts in an elderly patient are more likely to indicate malignancy. [18]
For patient education information, see the Cancer and Tumors Center, as well as Ovarian Cancer.
The primary use of CT scanning is in the evaluation of metastatic disease rather than of the ovarian mass; for the evaluation of the ovarian mass, ultrasonography and MRI are more valuable. [1] CT scanning is helpful in diagnosing cystic teratomas, 93% of which contain fat and 56% of which are calcified. If a large (>10 cm) soft-tissue mass is present, malignant transformation should be suspected. [19]
CT scanning also can aid in the evaluation of cystadenomas. A serous cystadenoma has an attenuation similar to that of water, whereas a mucinous cystadenoma has an attenuation closer to that of soft tissue.
The presence of wall and septal thickness and irregularity, as well as the existence of enhancing nodules, suggests malignancy. Although CT scan findings can suggest malignancy, they are not definitive for diagnosis unless metastases are present.
CT scan findings of complex functional cysts, benign ovarian tumors, and inflammatory and/or infectious masses, such as tubo-ovarian abscesses, can mimic ovarian malignancies.
Patients with a new diagnosis of epithelial ovarian cancer are routinely imaged with CT as a part of the initial work-up [4] , and CT is part of the standard of care in patients with high-grade serous ovarian cancer (HGSOC high-grade serous ovarian cancer), where it typically serves as a guide to surgical debulking and to assess response to chemotherapy. Because of frequent diagnosis of HGSOC high-grade serous ovarian cancer at the advanced stage, CT images typically display transcoelomic spread, usually over serosal and peritoneal surfaces. [20]
The primary advantage of using MRI in the evaluation of ovarian masses is the ability to employ this modality in the characterization of tissue. The presence of fat, hemorrhage, mucin, fluid, and solid tissue within an ovarian mass can be determined with the aid of MRI. The ability to characterize tissue in this way is most useful in determining whether a mass is definitely benign. [1, 9]
To determine the potential of malignancy for epithelial tumors, assessing the internal architecture is useful. In this situation, for example, gadolinium enhancement can be employed in the differentiation of solid papillary tissue (which can enhance) from clot or debris (which does not). Gadolinium enhancement is useful in the evaluation of the internal architecture of predominantly cystic lesions. In addition, if the mass is malignant, gadolinium enhancement may aid in the depiction of peritoneal implants.
Obtain images in at least 2 planes with T1- and T2-weighted sequences. [1]
For masses with high signal intensity on T1-weighted images, the addition of fat-saturated, T1-weighted images is useful in differentiating fat from hemorrhage. [1] If the signal intensity of a lesion is high on the T1-weighted image, the lesion can contain fat, hemorrhage, or mucin. If the lesion loses signal intensity after fat saturation, it contains fat; most likely, it is a cystic teratoma. If it does not lose signal, the lesion most likely contains hemorrhage, and it may represent an endometrioma or hemorrhagic cyst. Endometriomas are often dark on T2-weighted images. [21] In addition, high-viscosity mucin can be bright on T1-weighted images. Low-viscosity mucin is dark on T1-weighted images. [22]
If a lesion is dark on T1- and T2-weighted images, it may contain fibrotic tissue and be a fibroma. Consider a fibrothecoma or Brenner tumor.
Gadolinium-based contrast agents have been linked to the development of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD). The disease has occurred in patients with moderate to end-stage renal disease after being given a gadolinium-based contrast agent to enhance MRI or magnetic resonance angiography (MRA) scans. NSF/NFD is a debilitating and sometimes fatal disease. Characteristics include red or dark patches on the skin; burning, itching, swelling, hardening, and tightening of the skin; yellow spots on the whites of the eyes; joint stiffness with trouble moving or straightening the arms, hands, legs, or feet; pain deep in the hip bones or ribs; and muscle weakness.
In a multivariate analysis, the accuracy of gadolinium-enhanced MRI in the diagnosis of ovarian malignancy was 93%. [23] The findings most predictive of malignancy were necrosis in a solid lesion (odds ratio, 107) and vegetations in a cystic lesion (odds ratio, 40). In addition, ancillary findings, such as ascites, peritoneal metastases, and hemorrhage, on MRI scans had a high predictive value for malignancy. The use of gadolinium-based contrast agents improves tissue characterization and increases the degree of confidence for MRI findings.
As with CT scans, MRI scans may depict numerous benign processes, such as complex functional cysts, tubo-ovarian abscesses, and benign tumors, that can mimic an ovarian malignancy.
Malignant ovarian tumors tend to have papillary excrescences, irregular walls, and/or thick septations. [5, 1, 24, 25, 26] The tumor can contain echogenic material arising from mucin or protein debris. The more solid the areas are, the greater the likelihood that a tumor is present. Typically, intraperitoneal fluid is present; this is a sign of peritoneal spread.
On color Doppler ultrasonograms, tumors tend to have vessels with low impedance because of the lack of muscular media in the vessel wall and arteriovenous shunts. The vessels tend to be clustered.
(See the images and video below.)
The ultrasonographic finding that is most indicative of ovarian cancer is papillary excrescence, which is present in more than 50% of ovarian malignancies. Low impedance and clustered vessels have a 70-80% diagnostic accuracy. [7]
Tubo-ovarian abscesses may mimic the ultrasonographic appearance of ovarian cancer, but patients with abscesses typically present with symptoms that are attributable to an inflammatory process.
Jeong YY, Outwater EK, Kang HK. Imaging evaluation of ovarian masses. Radiographics. 2000 Sep-Oct. 20(5):1445-70. [Medline]. [Full Text].
Timmerman D, Ameye L, Fischerova D, Epstein E, Melis GB, Guerriero S, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ. 2010 Dec 14. 341:c6839. [Medline].
Nunes N, Ambler G, Foo X, Naftalin J, Widschwendter M, Jurkovic D. Use of IOTA simple rules for diagnosis of ovarian cancer: meta-analysis. Ultrasound Obstet Gynecol. 2014 Nov. 44 (5):503-14. [Medline].
Nougaret S, Lakhman Y, Gönen M, Goldman DA, Miccò M, D’Anastasi M, et al. High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes. Radiology. 2017 Nov. 285 (2):472-481. [Medline]. [Full Text].
Woodward ER, Sleightholme HV, Considine AM, et al. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG. 2007 Dec. 114(12):1500-9. [Medline].
Fleischer A. Ovarian cancer. Fleischer AC, Javitt MC, Jeffrey RB Jr, et al, eds. Clinical Gynecologic Imaging. Philadelphia, Pa: Lippincott Williams & Wilkins; 1996: 107.
Yazbek J, Raju SK, Ben-Nagi J, et al. Effect of quality of gynaecological ultrasonography on management of patients with suspected ovarian cancer: a randomised controlled trial. Lancet Oncol. 2008 Feb. 9(2):124-31. [Medline].
Choi JI, Park SB, Han BH, Kim YH, Lee YH, Park HJ, et al. Imaging features of complex solid and multicystic ovarian lesions: proposed algorithm for differential diagnosis. Clin Imaging. 2015 Jul 17. [Medline].
Mansour SM, Saraya S, El-Faissal Y. Semi-quantitative contrast-enhanced MR analysis of indeterminate ovarian tumours: when to say malignancy?. Br J Radiol. 2015 Sep. 88 (1053):20150099. [Medline].
Epstein E, van Calster B, Timmerman D, Nikman S. Subjective ultrasound assessment, the ADNEX model and ultrasound guided tru-cut biopsy to differentiate disseminated primary ovarian cancer metastatic non-ovarian cancer. Ultrasound Obstet Gynecol. 2015 Apr 29. [Medline].
Fischerova D, Burgetova A. Imaging techniques for the evaluation of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2014 Jul. 28 (5):697-720. [Medline].
[Guideline] Expert Panel on Women’s Imaging:., Pandharipande PV, Lowry KP, Reinhold C, Atri M, Benson CB, et al. ACR Appropriateness Criteria® Ovarian Cancer Screening. J Am Coll Radiol. 2017 Nov. 14 (11S):S490-S499. [Medline]. [Full Text].
[Guideline] Expert Panel on Women’s Imaging: Atri M, Alabousi A, Reinhold C, et al. ACR Appropriateness Criteria® Clinically Suspected Adnexal Mass, No Acute Symptoms. American College of Radiology. Available at https://acsearch.acr.org/docs/69466/Narrative/. 2018; Accessed: December 26, 2018.
[Guideline] Expert Panel on Women’s Imaging:., Kang SK, Reinhold C, Atri M, et al. ACR Appropriateness Criteria® Staging and Follow-Up of Ovarian Cancer. J Am Coll Radiol. 2018 May. 15 (5S):S198-S207. [Medline]. [Full Text].
Summaries for patients. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2012 Dec 18. 157 (12):I-56. [Medline].
Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016 Oct. 143 (1):3-15. [Medline].
[Guideline] National Comprehensive Cancer Network. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.. November 9, 2017; Accessed: February 27, 2019.
American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol. 2011 Mar. 117 (3):742-6. [Medline].
Buy JN, Ghossain MA, Moss AA, et al. Cystic teratoma of the ovary: CT detection. Radiology. 1989 Jun. 171(3):697-701. [Medline]. [Full Text].
Vargas HA, Huang EP, Lakhman Y, Ippolito JE, Bhosale P, Mellnick V, et al. Radiogenomics of High-Grade Serous Ovarian Cancer: Multireader Multi-Institutional Study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group. Radiology. 2017 Nov. 285 (2):482-492. [Medline]. [Full Text].
Kitajima K, Kaji Y, Kuwata Y, et al. Magnetic resonance imaging findings of endometrioid adenocarcinoma of the ovary. Radiat Med. 2007 Aug 1. 25(7):346-54. [Medline].
Okamoto Y, Tanaka YO, Tsunoda H, et al. Malignant or borderline mucinous cystic neoplasms have a larger number of loculi than mucinous cystadenoma: a retrospective study with MR. J Magn Reson Imaging. 2007 Jul. 26(1):94-9. [Medline].
Hricak H, Chen M, Coakley FV, et al. Complex adnexal masses: detection and characterization with MR imaging–multivariate analysis. Radiology. 2000 Jan. 214(1):39-46. [Medline]. [Full Text].
Bourne TH, Campbell S, Reynolds KM, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ. 1993 Apr 17. 306(6884):1025-9. [Medline]. [Full Text].
Fleischer AC, Cullinan JA, Peery CV, et al. Early detection of ovarian carcinoma with transvaginal color Doppler ultrasonography. Am J Obstet Gynecol. 1996 Jan. 174(1 Pt 1):101-6. [Medline].
Schulman H, Conway C, Zalud I, et al. Prevalence in a volunteer population of pelvic cancer detected with transvaginal ultrasound and color flow Doppler. Ultrasound Obstet Gynecol. 1994 Sep 1. 4(5):414-20. [Medline].
Iyer VR, Lee SI. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. AJR Am J Roentgenol. 2010 Feb. 194 (2):311-21. [Medline].
Tanaka YO, Okada S, Yagi T, Satoh T, Oki A, Tsunoda H, et al. MRI of endometriotic cysts in association with ovarian carcinoma. AJR Am J Roentgenol. 2010 Feb. 194 (2):355-61. [Medline].
Arthur C Fleischer, MD Professor, Chief of Ultrasound Imaging, Departments of Radiology and Radiological sciences and Obstetrics and Gynecology, Vanderbilt University Medical Center
Arthur C Fleischer, MD is a member of the following medical societies: American College of Radiology, American Institute of Ultrasound in Medicine, Society of Radiologists in Ultrasound
Disclosure: Nothing to disclose.
Eugene C Lin, MD Attending Radiologist, Teaching Coordinator for Cardiac Imaging, Radiology Residency Program, Virginia Mason Medical Center; Clinical Assistant Professor of Radiology, University of Washington School of Medicine
Eugene C Lin, MD is a member of the following medical societies: American College of Nuclear Medicine, American College of Radiology, Radiological Society of North America, Society of Nuclear Medicine and Molecular Imaging
Disclosure: Nothing to disclose.
Bernard D Coombs, MB, ChB, PhD Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand
Disclosure: Nothing to disclose.
Karen L Reuter, MD, FACR Professor, Department of Radiology, Lahey Clinic Medical Center
Karen L Reuter, MD, FACR is a member of the following medical societies: American Association for Women Radiologists, American College of Radiology, American Institute of Ultrasound in Medicine, American Roentgen Ray Society, Radiological Society of North America
Disclosure: Nothing to disclose.
Eugene C Lin, MD Attending Radiologist, Teaching Coordinator for Cardiac Imaging, Radiology Residency Program, Virginia Mason Medical Center; Clinical Assistant Professor of Radiology, University of Washington School of Medicine
Eugene C Lin, MD is a member of the following medical societies: American College of Nuclear Medicine, American College of Radiology, Radiological Society of North America, Society of Nuclear Medicine and Molecular Imaging
Disclosure: Nothing to disclose.
Harris L Cohen, MD, FACR Chairman, Department of Radiology, Professor of Radiology, Pediatrics, and Obstetrics and Gynecology, University of Tennessee Health Science Center College of Medicine; Radiologist-in-Chief, LeBonheur Children’s Hospital; Emeritus Professor of Radiology, The School of Medicine at Stony Brook University
Harris L Cohen, MD, FACR is a member of the following medical societies: American College of Radiology, American Institute of Ultrasound in Medicine, Radiological Society of North America, Society for Pediatric Radiology, Association of Program Directors in Radiology, Society of Radiologists in Ultrasound
Disclosure: Nothing to disclose.
Malignant Ovarian Tumor Imaging
Research & References of Malignant Ovarian Tumor Imaging |A&C Accounting And Tax Services
Source
0 Comments